1253 related articles for article (PubMed ID: 22827246)
1. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
Pliaka V; Kyriakopoulou Z; Markoulatos P
Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
[TBL] [Abstract][Full Text] [Related]
2. [Worldwide eradication of poliomyelitis].
Rasch G; Schreier E; Kiehl W; Kurth R
Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
[TBL] [Abstract][Full Text] [Related]
3. [End phase challenges of poliomyelitis eradication programme realization].
Jarzabek Z
Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
[TBL] [Abstract][Full Text] [Related]
4. [Universal use of inactivated poliovirus vaccine--the needs and challenges].
Shimizu H; Takeda N
Nihon Rinsho; 2008 Oct; 66(10):1950-5. PubMed ID: 18939495
[TBL] [Abstract][Full Text] [Related]
5. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.
Minor P
Vaccine; 2009 May; 27(20):2649-52. PubMed ID: 19428874
[TBL] [Abstract][Full Text] [Related]
7. A developing country perspective on vaccine-associated paralytic poliomyelitis.
John TJ
Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
[TBL] [Abstract][Full Text] [Related]
8. Polio eradication: the OPV paradox.
Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
[TBL] [Abstract][Full Text] [Related]
9. Risk management in a polio-free world.
Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
[TBL] [Abstract][Full Text] [Related]
10. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
[TBL] [Abstract][Full Text] [Related]
11. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
12. Immunization against poliomyelitis: risk/benefit/cost in a changing context.
Salk J
Dev Biol Stand; 1979; 43():151-7. PubMed ID: 230106
[TBL] [Abstract][Full Text] [Related]
13. Vaccine-derived polioviruses and the endgame strategy for global polio eradication.
Kew OM; Sutter RW; de Gourville EM; Dowdle WR; Pallansch MA
Annu Rev Microbiol; 2005; 59():587-635. PubMed ID: 16153180
[TBL] [Abstract][Full Text] [Related]
14. World wide experience with inactivated poliovirus vaccine.
Bonnet MC; Dutta A
Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
[TBL] [Abstract][Full Text] [Related]
15. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
[TBL] [Abstract][Full Text] [Related]
16. Modeling the dynamics of oral poliovirus vaccine cessation.
Thompson KM; Duintjer Tebbens RJ
J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
[TBL] [Abstract][Full Text] [Related]
17. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
Friedrich F
Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
[TBL] [Abstract][Full Text] [Related]
18. The polio endgame.
Minor P
Hum Vaccin Immunother; 2014; 10(7):2106-8. PubMed ID: 25608050
[TBL] [Abstract][Full Text] [Related]
19. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
20. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
Shimizu H
Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]